Efficacy and safety of fluocinolone acetonide intravitreal implant (0.2 µg/day) in patients with post-surgical inflammation associated with macular edema: a case series study
Abstract Background Postoperative cystoid macular edema (PCME) is a primary cause of reduced vision following both cataract and/or vitreoretinal surgery, which may spontaneously resolve. This study aimed to evaluate the effectiveness and safety of the fluocinolone acetonide intravitreal (FAc) implan...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-08-01
|
| Series: | Journal of Ophthalmic Inflammation and Infection |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12348-025-00503-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849234113036288000 |
|---|---|
| author | Maria Madeira Ana Cabugueira Helena Urbano Miguel Cordeiro Marta Guedes |
| author_facet | Maria Madeira Ana Cabugueira Helena Urbano Miguel Cordeiro Marta Guedes |
| author_sort | Maria Madeira |
| collection | DOAJ |
| description | Abstract Background Postoperative cystoid macular edema (PCME) is a primary cause of reduced vision following both cataract and/or vitreoretinal surgery, which may spontaneously resolve. This study aimed to evaluate the effectiveness and safety of the fluocinolone acetonide intravitreal (FAc) implant (0.2 µg/day) in patients with refractory PCME. Methods Retrospective, non-interventional, and single center study conducted on patients with PCME treated with 0.2 µg/day FAc implant. All the patients received previous treatment with topical corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), triancinolone injection and dexamethasone implant. The primary end-points were the mean change in best-corrected-visual-acuity (BCVA) and the proportion of patients gaining ≥ 15 letters from baseline to the last follow-up visit. The secondary endpoints included the mean CRT reduction and the mean intraocular pressure (IOP) during the 36 months study period. Results Eight eyes from 8 patients were included in the study. Median (95% Confidence-interval) BCVA was significantly improved from 60.0 (50.05–69.95) letters at baseline to 80.15 (77.25-85.00) letters at month-36, p = 0.043. At the last follow-up visit, 5 (62.5%) eyes gained ≥ 15 letters, without any eye experiencing a loss of BCVA compared to baseline. There was significant CRT reduction from baseline (median: 497.5 μm; 95%CI: 380.0–596.0 μm) to month-36 (Median: 252.0 μm; 95%CI: 242.0–268.0 μm); p = 0.012. Regarding safety, IOP remained stable from baseline (median: 14.5mmHg; 95%Confidence-interval: 12.0–23.0 mmHg) to the last follow-up visit (median: 13.5mmHg; 95% Confidence-interval: 9.0–19.0 mm Hg); p = 0.123. Conclusions The FAc implant significantly improved both visual and anatomic outcomes, and was effective in preventing recurrences, while maintaining a reasonable safety profile, in PCME refractory to intravitreal triancinolone and dexamethasone. |
| format | Article |
| id | doaj-art-582831d651b04bf09c8f74aa3b61835b |
| institution | Kabale University |
| issn | 1869-5760 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Journal of Ophthalmic Inflammation and Infection |
| spelling | doaj-art-582831d651b04bf09c8f74aa3b61835b2025-08-20T04:03:17ZengSpringerOpenJournal of Ophthalmic Inflammation and Infection1869-57602025-08-011511810.1186/s12348-025-00503-8Efficacy and safety of fluocinolone acetonide intravitreal implant (0.2 µg/day) in patients with post-surgical inflammation associated with macular edema: a case series studyMaria Madeira0Ana Cabugueira1Helena Urbano2Miguel Cordeiro3Marta Guedes4Ophthalmology Department, West Lisbon Local Health Unit (Unidade de Saúde Local de Lisboa Ocidental)Ophthalmology Department, West Lisbon Local Health Unit (Unidade de Saúde Local de Lisboa Ocidental)Ophthalmology Department, West Lisbon Local Health Unit (Unidade de Saúde Local de Lisboa Ocidental)Ophthalmology Department, West Lisbon Local Health Unit (Unidade de Saúde Local de Lisboa Ocidental)Ophthalmology Department, West Lisbon Local Health Unit (Unidade de Saúde Local de Lisboa Ocidental)Abstract Background Postoperative cystoid macular edema (PCME) is a primary cause of reduced vision following both cataract and/or vitreoretinal surgery, which may spontaneously resolve. This study aimed to evaluate the effectiveness and safety of the fluocinolone acetonide intravitreal (FAc) implant (0.2 µg/day) in patients with refractory PCME. Methods Retrospective, non-interventional, and single center study conducted on patients with PCME treated with 0.2 µg/day FAc implant. All the patients received previous treatment with topical corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), triancinolone injection and dexamethasone implant. The primary end-points were the mean change in best-corrected-visual-acuity (BCVA) and the proportion of patients gaining ≥ 15 letters from baseline to the last follow-up visit. The secondary endpoints included the mean CRT reduction and the mean intraocular pressure (IOP) during the 36 months study period. Results Eight eyes from 8 patients were included in the study. Median (95% Confidence-interval) BCVA was significantly improved from 60.0 (50.05–69.95) letters at baseline to 80.15 (77.25-85.00) letters at month-36, p = 0.043. At the last follow-up visit, 5 (62.5%) eyes gained ≥ 15 letters, without any eye experiencing a loss of BCVA compared to baseline. There was significant CRT reduction from baseline (median: 497.5 μm; 95%CI: 380.0–596.0 μm) to month-36 (Median: 252.0 μm; 95%CI: 242.0–268.0 μm); p = 0.012. Regarding safety, IOP remained stable from baseline (median: 14.5mmHg; 95%Confidence-interval: 12.0–23.0 mmHg) to the last follow-up visit (median: 13.5mmHg; 95% Confidence-interval: 9.0–19.0 mm Hg); p = 0.123. Conclusions The FAc implant significantly improved both visual and anatomic outcomes, and was effective in preventing recurrences, while maintaining a reasonable safety profile, in PCME refractory to intravitreal triancinolone and dexamethasone.https://doi.org/10.1186/s12348-025-00503-8Postoperative cystoid macular edemaInflammationFluocinolone acetonide intravitreal implantILUVIENIntraocular inflammationIntraocular pressure |
| spellingShingle | Maria Madeira Ana Cabugueira Helena Urbano Miguel Cordeiro Marta Guedes Efficacy and safety of fluocinolone acetonide intravitreal implant (0.2 µg/day) in patients with post-surgical inflammation associated with macular edema: a case series study Journal of Ophthalmic Inflammation and Infection Postoperative cystoid macular edema Inflammation Fluocinolone acetonide intravitreal implant ILUVIEN Intraocular inflammation Intraocular pressure |
| title | Efficacy and safety of fluocinolone acetonide intravitreal implant (0.2 µg/day) in patients with post-surgical inflammation associated with macular edema: a case series study |
| title_full | Efficacy and safety of fluocinolone acetonide intravitreal implant (0.2 µg/day) in patients with post-surgical inflammation associated with macular edema: a case series study |
| title_fullStr | Efficacy and safety of fluocinolone acetonide intravitreal implant (0.2 µg/day) in patients with post-surgical inflammation associated with macular edema: a case series study |
| title_full_unstemmed | Efficacy and safety of fluocinolone acetonide intravitreal implant (0.2 µg/day) in patients with post-surgical inflammation associated with macular edema: a case series study |
| title_short | Efficacy and safety of fluocinolone acetonide intravitreal implant (0.2 µg/day) in patients with post-surgical inflammation associated with macular edema: a case series study |
| title_sort | efficacy and safety of fluocinolone acetonide intravitreal implant 0 2 µg day in patients with post surgical inflammation associated with macular edema a case series study |
| topic | Postoperative cystoid macular edema Inflammation Fluocinolone acetonide intravitreal implant ILUVIEN Intraocular inflammation Intraocular pressure |
| url | https://doi.org/10.1186/s12348-025-00503-8 |
| work_keys_str_mv | AT mariamadeira efficacyandsafetyoffluocinoloneacetonideintravitrealimplant02μgdayinpatientswithpostsurgicalinflammationassociatedwithmacularedemaacaseseriesstudy AT anacabugueira efficacyandsafetyoffluocinoloneacetonideintravitrealimplant02μgdayinpatientswithpostsurgicalinflammationassociatedwithmacularedemaacaseseriesstudy AT helenaurbano efficacyandsafetyoffluocinoloneacetonideintravitrealimplant02μgdayinpatientswithpostsurgicalinflammationassociatedwithmacularedemaacaseseriesstudy AT miguelcordeiro efficacyandsafetyoffluocinoloneacetonideintravitrealimplant02μgdayinpatientswithpostsurgicalinflammationassociatedwithmacularedemaacaseseriesstudy AT martaguedes efficacyandsafetyoffluocinoloneacetonideintravitrealimplant02μgdayinpatientswithpostsurgicalinflammationassociatedwithmacularedemaacaseseriesstudy |